COL9A1 — Collagen type IX alpha 1 chain

The COL9A1 gene provides instructions for making a part of a protein called type IX collagen. Collagens are a family of proteins that act like the scaffolding or glue in the body, providing strength and support to connective tissues. Type IX collagen is especially important in cartilage, the tough but flexible tissue that cushions the ends of bones, and in the vitreous, the clear, jelly-like substance that fills the inside of the eye. It helps connect different parts of the tissue together, keeping them stable and working properly. When there is a mutation (a harmful change) in the COL9A1 gene, the body either makes abnormal type IX collagen or doesn't make enough of it. This weakens the connective tissues. Depending on the specific mutation and how it is inherited, this can lead to different health conditions. If a person inherits two mutated copies of the gene (one from each parent), they may develop a condition called Stickler syndrome. This can cause severe nearsightedness, a high risk of retinal detachment (where the back of the eye pulls away), hearing loss, and joint problems. If a person inherits just one mutated copy, they might develop multiple epiphyseal dysplasia, a condition that mainly causes joint pain and early arthritis. For patients and families, a diagnosis related to the COL9A1 gene means that regular medical check-ups are very important. Because of the high risk of eye problems, especially retinal detachment in Stickler syndrome, frequent visits to an eye doctor are crucial to catch and treat any issues early before they cause vision loss. Hearing tests and joint evaluations are also recommended to manage symptoms and improve quality of life. Genetic counseling can help families understand how the condition is passed down and what the risks might be for other family members.

Gene description: Encodes the alpha-1 chain of type IX collagen, a minor fibrillar collagen associated with type II collagen.

Patient and family guide: The COL9A1 gene provides instructions for making a part of a protein called type IX collagen. Collagens are a family of proteins that act like the scaffolding or glue in the body, providing strength and support to connective tissues. Type IX collagen is especially important in cartilage, the tough but flexible tissue that cushions the ends of bones, and in the vitreous, the clear, jelly-like substance that fills the inside of the eye. It helps connect different parts of the tissue together, keeping them stable and working properly. When there is a mutation (a harmful change) in the COL9A1 gene, the body either makes abnormal type IX collagen or doesn't make enough of it. This weakens the connective tissues. Depending on the specific mutation and how it is inherited, this can lead to different health conditions. If a person inherits two mutated copies of the gene (one from each parent), they may develop a condition called Stickler syndrome. This can cause severe nearsightedness, a high risk of retinal detachment (where the back of the eye pulls away), hearing loss, and joint problems. If a person inherits just one mutated copy, they might develop multiple epiphyseal dysplasia, a condition that mainly causes joint pain and early arthritis. For patients and families, a diagnosis related to the COL9A1 gene means that regular medical check-ups are very important. Because of the high risk of eye problems, especially retinal detachment in Stickler syndrome, frequent visits to an eye doctor are crucial to catch and treat any issues early before they cause vision loss. Hearing tests and joint evaluations are also recommended to manage symptoms and improve quality of life. Genetic counseling can help families understand how the condition is passed down and what the risks might be for other family members.

Gene function: COL9A1 is expressed in the vitreous humor and is involved in its structural integrity by interacting with type II collagen. It helps maintain the vitreous gel and its attachment to the retina. Mutations can lead to vitreoretinal disorders and an increased risk of retinal detachment.

Protein structure: The COL9A1 gene encodes the α1 chain of type IX collagen, which is approximately 922 amino acids in length. The protein is characterized by three triple-helical collagenous domains (COL1, COL2, and COL3) that are interspersed with four non-collagenous (globular) domains (NC1, NC2, NC3, and NC4). The NC4 domain is located at the N-terminus and is unique to the α1(IX) chain; it is not present in the α2 or α3 chains. This domain is thought to interact with other matrix components. Type IX collagen assembles as a heterotrimer, consisting of one α1(IX), one α2(IX), and one α3(IX) chain. The assembly is guided by the non-collagenous domains, particularly the NC2 domain, which determines the chain composition and register of the triple helix. The protein undergoes significant post-translational modifications, including the hydroxylation of proline and lysine residues, which are essential for the stability of the triple helix. Additionally, the α1(IX) chain can be modified by the attachment of a glycosaminoglycan (GAG) chain, classifying type IX collagen as a proteoglycan.

Molecular function: The COL9A1 gene encodes the α1 chain of type IX collagen, a fibril-associated collagen with interrupted triple helices (FACIT). Type IX collagen is a heterotrimeric molecule composed of one α1(IX), one α2(IX), and one α3(IX) chain. Its primary molecular function is to serve as a structural bridge within the extracellular matrix, particularly in cartilage and the vitreous of the eye. It binds covalently to the surface of type II collagen fibrils, which are the major structural components of these tissues. By interacting with type II collagen and other matrix proteins, such as COMP (cartilage oligomeric matrix protein) and MATN3 (matrilin-3), type IX collagen helps to stabilize the collagen fibril network and mediate interactions between the fibrils and the surrounding extrafibrillar matrix. The α1(IX) chain also contains a covalently attached glycosaminoglycan (GAG) side chain, making type IX collagen a proteoglycan. This GAG chain contributes to the hydration and biomechanical properties of the tissue. In the eye, the structural integrity provided by type IX collagen is crucial for maintaining the clear, gel-like consistency of the vitreous and its attachment to the retina, preventing vitreoretinal degeneration and retinal detachment.

Expression pattern: The COL9A1 gene is expressed in tissues that are rich in hyaline cartilage, as well as in the vitreous humor of the eye and the inner ear. During development, it is highly expressed in the cartilage anlagen of the skeleton, which is later largely replaced by bone, though expression persists in the articular cartilage covering the ends of bones. The gene is also expressed in the intervertebral discs. In the eye, COL9A1 is expressed in the vitreous body, where type IX collagen interacts with type II collagen to maintain the gel-like structure and transparency of the vitreous. Its expression in the inner ear is consistent with the sensorineural hearing loss observed in patients with COL9A1 mutations. The tissue-specific expression pattern directly correlates with the clinical manifestations of COL9A1-related disorders, which primarily affect the joints, eyes, and auditory system.

Mutation spectrum: The mutation spectrum of the COL9A1 gene includes nonsense, missense, splice-site, and frameshift mutations, as well as small insertions and deletions. Pathogenic variants are distributed across the gene, affecting various domains of the α1(IX) protein. Nonsense mutations, which introduce a premature stop codon and lead to a truncated or absent protein, are frequently associated with autosomal recessive Stickler syndrome. Splice-site mutations, which can cause in-frame deletions of specific exons, are more commonly linked to autosomal dominant multiple epiphyseal dysplasia. These mutations often disrupt the collagenous domains, interfering with the proper folding and assembly of the triple helix. While the total number of known pathogenic variants is relatively small compared to other collagen genes like COL2A1, they are critical for understanding the distinct phenotypic outcomes associated with different types of genetic alterations in COL9A1.

Pathogenic variants: 1. p.Arg295Ter (c.883C>T) - A nonsense mutation that leads to a premature stop codon, resulting in a loss of function. When homozygous, it causes autosomal recessive Stickler syndrome (type IV), characterized by severe myopia, hearing loss, and epiphyseal dysplasia. 2. p.Arg507Ter (c.1519C>T) - Another nonsense mutation that, in a homozygous state, is associated with autosomal recessive Stickler syndrome, presenting with similar ocular, auditory, and skeletal features. 3. c.1071+3_1071+4insT (IVS8+3insT) - A splice-site mutation that causes in-frame deletions of the COL3 domain. This heterozygous mutation exerts a dominant-negative effect and is associated with autosomal dominant multiple epiphyseal dysplasia (MED).

Clinical significance: Mutations in the COL9A1 gene are primarily associated with two distinct clinical conditions: autosomal recessive Stickler syndrome (type IV) and autosomal dominant multiple epiphyseal dysplasia (MED). Stickler syndrome type IV is a connective tissue disorder characterized by moderate to severe sensorineural hearing loss, moderate to high myopia, vitreoretinopathy, and epiphyseal dysplasia. A significant ocular complication in these patients is a high risk of rhegmatogenous retinal detachment, which can occur early in life and lead to vision loss if not treated promptly. Multiple epiphyseal dysplasia caused by COL9A1 mutations is a disorder of cartilage and bone development that primarily affects the ends of the long bones (epiphyses) in the arms and legs. Patients typically present with joint pain, early-onset osteoarthritis, and mild short stature. The severity and specific manifestations can vary, but the condition generally impacts mobility and joint function. The dual involvement of the eye and skeletal system in COL9A1-related disorders underscores the critical role of type IX collagen in maintaining the structural integrity of both the vitreous humor and articular cartilage.

Inheritance: Autosomal dominant

Chromosomal location: 6q13

Genotype-phenotype correlations: Genotype-phenotype correlations for COL9A1 mutations are largely defined by the inheritance pattern and the nature of the mutation. Homozygous or compound heterozygous loss-of-function mutations, such as nonsense mutations (e.g., p.Arg295Ter), typically result in autosomal recessive Stickler syndrome (type IV). This condition is characterized by a severe phenotype that includes significant ocular involvement (myopia, vitreoretinopathy, retinal detachment), sensorineural hearing loss, and joint issues. The complete loss of functional type IX collagen appears to be necessary for this systemic presentation. In contrast, heterozygous mutations, particularly those affecting splicing (e.g., splice-site mutations leading to in-frame deletions), are associated with autosomal dominant multiple epiphyseal dysplasia (MED). These mutations likely exert a dominant-negative effect, where the abnormal α1(IX) chains incorporate into and disrupt the assembly or function of the heterotrimeric type IX collagen molecules. This dominant-negative mechanism primarily affects the articular cartilage, leading to joint dysplasia and early-onset osteoarthritis, with less pronounced or absent ocular and auditory features compared to the recessive Stickler syndrome phenotype.

Research and therapeutic approaches: Currently, there are no FDA-approved gene therapies or targeted molecular treatments specifically for COL9A1-related disorders. Management is primarily symptomatic and supportive, focusing on the specific clinical manifestations. For patients with Stickler syndrome, prophylactic laser photocoagulation or cryotherapy may be used to treat retinal tears and prevent retinal detachment, which is a major cause of vision loss in these individuals. If retinal detachment occurs, surgical intervention is required. Hearing aids are utilized for sensorineural hearing loss, and joint pain or early-onset osteoarthritis is managed with physical therapy, pain medications, and eventually joint replacement surgery if necessary. Research into therapeutic approaches for collagenopathies is ongoing, though much of the focus has been on more common collagen disorders. Potential future strategies could include gene therapy approaches, such as gene replacement for recessive loss-of-function mutations or CRISPR/Cas9 gene editing to correct specific variants. Antisense oligonucleotides (ASOs) or RNA interference (RNAi) could theoretically be explored to silence the mutant allele in dominant-negative forms of the disease, such as multiple epiphyseal dysplasia. However, these approaches are still in the preclinical stages for COL9A1, and significant hurdles remain, particularly regarding the effective delivery of therapies to avascular tissues like cartilage and the complex structure of the eye.

Diagnostic testing: Mutations in the COL9A1 gene are typically detected through molecular genetic testing, which can include targeted gene panels for Stickler syndrome, multiple epiphyseal dysplasia, or inherited retinal diseases. Whole exome sequencing (WES) or whole genome sequencing (WGS) may also be employed, particularly when the clinical presentation is broad or overlaps with other connective tissue disorders. Deletion/duplication analysis is sometimes necessary to identify larger structural variants that might be missed by standard sequencing. Genetic counseling is an essential component of the diagnostic process. For autosomal recessive Stickler syndrome, parents of an affected individual are obligate carriers, and there is a 25% chance with each pregnancy of having another affected child. For autosomal dominant multiple epiphyseal dysplasia, an affected individual has a 50% chance of passing the mutation to their offspring. Early diagnosis through genetic testing allows for proactive monitoring and management of complications, such as regular ophthalmologic exams to detect and treat retinal tears before they progress to full detachment, and audiologic assessments for hearing loss.

Animal models: The primary animal model used to study COL9A1 function is the Col9a1 knockout mouse. These mice do not produce α1(IX) mRNA or polypeptides and are born without conspicuous skeletal abnormalities, but they postnatally develop early-onset osteoarthritis and intervertebral disc degeneration. The absence of the α1(IX) chain leads to a functional knockout of all type IX collagen polypeptides, demonstrating that the α1 chain is essential for the assembly of the heterotrimeric collagen IX molecule. While cartilage fibrils still form in these mice, the lack of type IX collagen compromises long-term tissue stability, highlighting its role in mediating interactions between fibrillar and extrafibrillar macromolecules. Although the Col9a1 knockout mouse primarily exhibits joint and skeletal phenotypes, it serves as a crucial model for understanding the structural role of type IX collagen in connective tissues, including the vitreous of the eye. Zebrafish models have also been utilized broadly to study collagen-related disorders and extracellular matrix dynamics, though specific Col9a1 zebrafish models are less prominently featured in the literature compared to the established mouse models.

Population genetics: Pathogenic variants in the COL9A1 gene are rare in the general population. Autosomal recessive Stickler syndrome caused by COL9A1 mutations has been reported in a limited number of families, often with a history of consanguinity (parents who are closely related), which increases the likelihood of inheriting two copies of a rare recessive mutation. Specific founder mutations have not been widely established for COL9A1, but certain variants, such as the p.Arg295Ter mutation, have been identified in multiple families of Moroccan descent, suggesting a possible shared ancestry or founder effect in that specific population. Carrier frequencies for these rare variants are generally very low across global populations.

Selected references: 1. Van Camp G, et al. A new autosomal recessive form of Stickler syndrome is caused by a mutation in the COL9A1 gene. Am J Hum Genet. 2006;79(3):449-457. PMID: 16909383 2. Czarny-Ratajczak M, et al. A mutation in COL9A1 causes multiple epiphyseal dysplasia: further evidence for locus heterogeneity. Am J Hum Genet. 2001;69(5):969-980. PMID: 11565064 3. Nikopoulos K, et al. Autosomal recessive Stickler syndrome in two families is caused by mutations in the COL9A1 gene. Invest Ophthalmol Vis Sci. 2011;52(7):4774-4779. PMID: 21421862 4. Fassler R, et al. Mice lacking alpha 1 (IX) collagen develop noninflammatory degenerative joint disease. Proc Natl Acad Sci U S A. 1994;91(11):5070-5074. PMID: 8197187 5. Nixon TRW, et al. Homozygous Type IX collagen variants (COL9A1, COL9A2, and COL9A3) causing recessive Stickler syndrome-Expanding the phenotype. Am J Med Genet A. 2019;179(8):1498-1506. PMID: 31090205